| User's Publication |
|
19543
Thierry S, Maadadi S, Berton A, Dimier L, Perret C, Vey N, Ourfali S, Saccas M, Caron S, Boucard-Jourdin M, Colombel M, Werle B, Bonnin M.
TL-532, a novel specific Toll-like receptor 3 agonist rationally designed for targeting cancers: discovery process and biological characterization
Microb Cell
2023
10(6):117-132
PubMed ID: 37275475
DOI: 10.15698/mic2023.06.797
|
|
17497
Nickless A, Zhang J, Othoum G, Webster J, Inkman MJ, Coonrod E, Fontes S, Rozycki EB, Maher CA, White NM.
Pan-Cancer Analysis Reveals Recurrent BCAR4 Gene Fusions across Solid Tumors
Mol Cancer Res
2022
20(10):1481-1488
PubMed ID: 35852383
DOI: 10.1158/1541-7786.MCR-21-0775
|
|
20629
Stransky LA, Vigeant SM, Huang B, West D, Denize T, Walton E, Signoretti S, Kaelin WG Jr.
Sensitivity of VHL mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway.
Proc Natl Acad Sci U S A
2022
119(14):e2120403119
PubMed ID: 35357972
DOI: 10.1073/pnas.2120403119
|
|
3741
Saleeb RM, Farag M, Lichner Z, Brimo F3, Bartlett J, Bjarnason G, Finelli A, Rontondo F, Downes MR, Yousef GM
Modulating ATP binding cassette transporters in papillary renal cell carcinoma type 2 enhances its response to targeted molecular therapy.
Mol Oncol
2018
12(10):1673-1688
PubMed ID: 29896907
DOI: 10.1002/1878-0261.12346
|
|
3747
Nagao K, Shinohara N, Smit F, de Weijert M, Jannink S, Owada Y, Mulders P, Oosterwijk E, Matsuyama H.
Fatty acid binding protein 7 may be a marker and therapeutic targets in clear cell renal cell carcinoma.
BMC Cancer.
2018
18(1):1114
PubMed ID: 30442117
DOI: 10.1186/s12885-018-5060-8
|
|
10184
Takaoka N, Takayama T, Ozono S.
Functional analysis of fatty acid binding protein 7 and its effect on fatty acid of renal cell carcinoma cell lines.
BMC Cancer
2017
17:192
PubMed ID: 28292269
DOI: 10.1186/s12885-017-3184-x
|
|
3745
Ning Z, Yongjing L, Yunzhen W, Zichuang Y, Qiang Z, Cheng W, Zhiqiang C, Yan X.
Optimization of cell lines as tumour models by integrating multi-omics data.
Brief Bioinform
2017
18(3):545
PubMed ID: 28013237
DOI: 10.1093/bib/bbw121
|
|
3743
Ando R, Tokuda N, Yamamoto T, Ikeda K, Hashimoto N, Taguchi R, Fan X, Furukawa K, Niimura Y, Suzuki A, Goto M, Furukawa K
Immunization of A4galt-deficient mice with glycosphingolipids from renal cell cancers resulted in the generation of anti-sulfoglycolipid monoclonal antibodies.
Glycoconj J
2016
33(2):169-80
PubMed ID: 26883028
DOI: 10.1007/s10719-016-9654-6
|
|
12964
Kato T, Inoue H, Imoto S, Tamada Y, Miyamoto T, Matsuo Y, Nakamura Y, Park JH.
Oncogenic roles of TOPK and MELK, and effective growth suppression by small molecular inhibitors in kidney cancer cells
Oncotarget
2016
7(14):17652-64
PubMed ID: 26933922
DOI: 10.18632/oncotarget.7755
|
|
3744
Nakamura R, Oyama T, Tajiri R, Mizokami A, Namiki M, Nakamoto M, Ooi A.
Expression and regulatory effects on cancer cell behavior of NELL1 and NELL2 in human renal cell carcinoma.
Cancer Sci
2015
106(5):656-64
PubMed ID: 25726761
DOI: 10.1111/cas.12649
|
|
3746
Li QC, Li HJ, Liu S, Liang Y, Wang X, Cui L.
Inhibition of γ-secretase by retinoic acid chalcone (RAC) induces G2/M arrest and triggers apoptosis in renal cell carcinoma.
Int J Clin Exp Pathol
2015
8(3):2400-7
PubMed ID: 26045747
|
|
6384
Hidenori Kawashima Sakae Masaki Marie Kawamura
Induction of HLA‑A* 33‑restricted cytotoxic lymphocytes against renal cell carcinoma targeting galectin 9 and PINCH
Biomedical Reports
2014
2:809-812
PubMed ID: 25279150
DOI: 10.3892/br.2014.334
|
|
15911
Tan C, Takayama T, Takaoka N, Fujita H, Miyazaki M, Sugiyama T, Ozono S.
Impact of Gender in Renal Cell Carcinoma: The Relationship of FABP7 and BRN2 Expression with Overall Survival
Clin Med Insights Oncol
2014
8:21-7
PubMed ID: 24653654
DOI: 10.4137/CMO.S13684
|
|
3516
Takaoka N, Takayama T, Teratani T, Sugiyama T, Mugiya S, Ozono S.
Analysis of the regulation of fatty acid binding protein 7 expression in human renal carcinoma cell lines.
BMC Mol Biol
2011
12:31
PubMed ID: 21771320
DOI: 10.1186/1471-2199-12-31
|
|
6387
Minami K, Chano T, Kawakami T, Ushida H, Kushima R, Okabe H, Okada Y, Okamoto K.
DNMT3L is a novel marker and is essential for the growth of human embryonal carcinoma.
Clin Cancer Res
2010
16(10):2751-9
PubMed ID: 20460473
DOI: 10.1158/1078-0432.CCR-09-3338
|
|
8851
Domoto T, Miyama Y, Suzuki H, Teratani T, Arai K, Sugiyama T, Takayama T, Mugiya S, Ozono S, Nozawa R.
Evaluation of S100A10, annexin II and B-FABP expression as markers for renal cell carcinoma.
Cancer Sci.
2007
98:77-82
PubMed ID: 17083565
DOI: 10.1111/j.1349-7006.2006.00355.x
|
|
3396
Yamada, Daisuke, Kikuchi, Shinji, Williams, Yuko N, Sakurai-Yageta, Mika, Masuda, Mari, Maruyama, Tomoko, Tomita, Kyoichi, Gutmann, David H, Kakizoe, Tadao, Kitamura, Tadaichi, Kanai, Yae, Murakami, Yoshinori
Promoter hypermethylation of the potential tumor suppressor DAL-1/4.1B gene in renal clear cell carcinoma.
Int J Cancer
2006
118:916-23
PubMed ID: 16152585
DOI: 10.1002/ijc.21450
|
|
5012
Kawakami T, Chano T, Minami K, Okabe H, Okada Y, Okamoto K.
Imprinted DLK1 is a putative tumor suppressor gene and inactivated by epimutation at the region upstream of GTL2 in human renal cell carcinoma.
Hum Mol Genet
2006
15(6):821-30
PubMed ID: 16439445
DOI: 10.1093/hmg/ddl001
|
|
14006
Hirota E, Yan L, Tsunoda T, Ashida S, Fujime M, Shuin T, Miki T, Nakamura Y, Katagiri T.
Genome-wide gene expression profiles of clear cell renal cell carcinoma: identification of molecular targets for treatment of renal cell carcinoma
Int J Oncol
2006
29(4):799-827.
PubMed ID: 16964377
|
|
6450
Tokinaga K, Okuda H, Nomura A, Ashida S, Furihata M, Shuin T.
Hypermethylation of the RASSF1A tumor suppressor gene in Japanese clear cell renal cell carcinoma.
Oncol Rep
2004
12(4):805-10
PubMed ID: 15375503
|
|
18700
Teratani T, Watanabe T, Kuwahara F, Kumagai H, Kobayashi S, Aoki U, Ishikawa A, Arai K, Nozawa R.
Induced transcriptional expression of calcium-binding protein S100A1 and S100A10 genes in human renal cell carcinoma
Cancer Lett
2002
175(1):71-7
PubMed ID: 11734338
DOI: 10.1016/s0304-3835(01)00724-8
|
Back
Top
CELL BANK Website
